| Literature DB >> 28125105 |
Xuefeng Liu1,2, Ewa Krawczyk1,2, Frank A Suprynowicz1,2, Nancy Palechor-Ceron1,2, Hang Yuan1,2, Aleksandra Dakic1,2, Vera Simic1,2, Yun-Ling Zheng3, Praathibha Sripadhan1,2, Chen Chen1,2, Jie Lu1,2, Tung-Wei Hou1,2, Sujata Choudhury1,2, Bhaskar Kallakury1,2, Dean G Tang4, Thomas Darling5, Rajesh Thangapazham5, Olga Timofeeva3,6, Anatoly Dritschilo6, Scott H Randell7, Christopher Albanese1,2,3, Seema Agarwal1,2, Richard Schlegel1,2.
Abstract
Historically, it has been difficult to propagate cells in vitro that are derived directly from human tumors or healthy tissue. However, in vitro preclinical models are essential tools for both the study of basic cancer biology and the promotion of translational research, including drug discovery and drug target identification. This protocol describes conditional reprogramming (CR), which involves coculture of irradiated mouse fibroblast feeder cells with normal and tumor human epithelial cells in the presence of a Rho kinase inhibitor (Y-27632). CR cells can be used for various applications, including regenerative medicine, drug sensitivity testing, gene expression profiling and xenograft studies. The method requires a pathologist to differentiate healthy tissue from tumor tissue, and basic tissue culture skills. The protocol can be used with cells derived from both fresh and cryopreserved tissue samples. As approximately 1 million cells can be generated in 7 d, the technique is directly applicable to diagnostic and predictive medicine. Moreover, the epithelial cells can be propagated indefinitely in vitro, yet retain the capacity to become fully differentiated when placed into conditions that mimic their natural environment.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28125105 PMCID: PMC6195120 DOI: 10.1038/nprot.2016.174
Source DB: PubMed Journal: Nat Protoc ISSN: 1750-2799 Impact factor: 13.491